UB Paderborn / Katalog / Suche / in CDI

Adjuvant and antigen delivery properties of virosomes

Current drug delivery, 2005-10, Vol.2 (4), p.395

2005

Volltextzugriff (PDF)

New perspectives for hepatitis B vaccines and immunization

Vaccine, 2009-05, Vol.27 (25), p.3271-3275

2009

Volltextzugriff (PDF)

Phase 1 Evaluation of Intranasal Virosomal Influenza Vaccine with and without Escherichia coli Heat-Labile Toxin in Adult Volunteers

Journal of Virology, 1999-09, Vol.73 (9), p.7780-7786

1999

Volltextzugriff (PDF)

Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine

Vaccine, 2009-07, Vol.27 (33), p.4381-4387

2009

Volltextzugriff (PDF)

In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus

International immunology, 2002-06, Vol.14 (6), p.615-626

2002

Volltextzugriff (PDF)

Rapid emergence of a viral resistant mutant in WHV chronically infected woodchucks treated with lamivudine and a pre-S/S CHO-derived hepatitis B virus vaccine

Vaccine, 2007-06, Vol.25 (26), p.4895-4902

2007

Volltextzugriff (PDF)

Delivery to cancer cells of antisense L‐ myc oligonucleotides incorporated in fusogenic, cationic‐lipid‐reconstituted influenza‐virus envelopes (cationic virosomes)

International journal of cancer, 1998-08, Vol.77 (5), p.728-733

1998

Volltextzugriff (PDF)

Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs

Current opinion in biotechnology, 2004-12, Vol.15 (6), p.518-529

2004

Volltextzugriff (PDF)

Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine

Expert review of vaccines, 2003-04, Vol.2 (2), p.295-304

2003

Volltextzugriff (PDF)

An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults

Clinical therapeutics, 2002, Vol.24 (1), p.100-111

2002

Volltextzugriff (PDF)

Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines

Vaccine, 1998-01, Vol.16 (2), p.298-304

1998

Volltextzugriff (PDF)

Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch

Vaccine, 2005-01, Vol.23 (7), p.946-950

2005

Volltextzugriff (PDF)

Inactivated virosome hepatitis A vaccine

The Lancet (British edition), 1994-02, Vol.343 (8893), p.322-324

1994

Volltextzugriff (PDF)

New perspectives in vaccination and immunotherapies for HBV infections

Procedia in vaccinology, 2009, Vol.1 (1), p.35-40

2009

Volltextzugriff (PDF)

New technology platforms in the development of vaccines for the future

Vaccine, 2002-12, Vol.20, p.B10-B16

2002

Volltextzugriff (PDF)

Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a

The Journal of infectious diseases, 2000-03, Vol.181 (3), p.1129

2000

Volltextzugriff (PDF)

Influenza virosomes as an efficient system for adjuvanted vaccine delivery

Expert opinion on biological therapy, 2004-07, Vol.4 (7), p.1139-1145

2004

Volltextzugriff (PDF)

Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs)

Vaccine, 1999-03, Vol.17 (13), p.1782-1787

Glueck, R

1999

Volltextzugriff (PDF)

H+-induced Membrane Insertion of Influenza Virus Hemagglutinin Involves the HA2 Amino-terminal Fusion Peptide but Not the Coiled Coil Region

The Journal of biological chemistry, 1996-06, Vol.271 (23), p.13417-13421

1996

Volltextzugriff (PDF)

Influenza-Impfstoffe-Bewährtes und Neues

International journal of public health, 1997-03, Vol.42 (2), p.S100

Glück, Reinhard

1997

Volltextzugriff (PDF)

A Virosome-Mimotope Approach to Synthetic Vaccine Design and Optimization: Synthesis, Conformation, and Immune Recognition of a Potential Malaria-Vaccine Candidate

Angewandte Chemie (International ed.), 2003-05, Vol.42 (21), p.2368-2371

2003

Volltextzugriff (PDF)

Safety and Immunogenicity of Intranasally Administered Inactivated Trivalent Virosome-Formulated Influenza Vaccine Containing Escherichia coli Heat-Labile Toxin as a Mucosal Adjuvant

The Journal of infectious diseases, 2000-03, Vol.181 (3), p.1129-1132

2000

Volltextzugriff (PDF)

Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine

Vaccine, 2004-10, Vol.22 (31), p.4390-4396

2004

Volltextzugriff (PDF)

Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents

Vaccine, 2003-07, Vol.21 (23), p.3169-3178

2003

Volltextzugriff (PDF)

Exploiting Conformationally Constrained Peptidomimetics and an Efficient Human-Compatible Delivery System in Synthetic Vaccine Design

Chembiochem : a European journal of chemical biology, 2001-11, Vol.2 (11), p.838-843

2001

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Adjuvant and antigen delivery properties of virosomes

New perspectives for hepatitis B vaccines and immunization

Phase 1 Evaluation of Intranasal Virosomal Influenza Vaccine with and without Escherichia coli Heat-Labile Toxin in Adult Volunteers

Eleven years of Inflexal® V—a virosomal adjuvanted influenza vaccine

In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus

Rapid emergence of a viral resistant mutant in WHV chronically infected woodchucks treated with lamivudine and a pre-S/S CHO-derived hepatitis B virus vaccine

Delivery to cancer cells of antisense L‐ myc oligonucleotides incorporated in fusogenic, cationic‐lipid‐reconstituted influenza‐virus envelopes (cationic virosomes)

Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs

Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine

An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults

Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines

Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch

Inactivated virosome hepatitis A vaccine

New perspectives in vaccination and immunotherapies for HBV infections

New technology platforms in the development of vaccines for the future

Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a

Influenza virosomes as an efficient system for adjuvanted vaccine delivery

Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs)

H+-induced Membrane Insertion of Influenza Virus Hemagglutinin Involves the HA2 Amino-terminal Fusion Peptide but Not the Coiled Coil Region

Influenza-Impfstoffe-Bewährtes und Neues

A Virosome-Mimotope Approach to Synthetic Vaccine Design and Optimization: Synthesis, Conformation, and Immune Recognition of a Potential Malaria-Vaccine Candidate

Safety and Immunogenicity of Intranasally Administered Inactivated Trivalent Virosome-Formulated Influenza Vaccine Containing Escherichia coli Heat-Labile Toxin as a Mucosal Adjuvant

Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine

Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents

Exploiting Conformationally Constrained Peptidomimetics and an Efficient Human-Compatible Delivery System in Synthetic Vaccine Design

Suchergebnisse filtern